Fig. 1. A roadmap to cancer proteotype discovery and utility.

A subset of 137 of 500 primary NSCLC tumors engrafted to yield PDX models. PDXs represent the most aggressive subset of NSCLC and were profiled for gene expression, gene copy number variation, DNA methylation, exome mutations, proteome and phosphotyrosine(pY)-proteome. Proteome profiling revealed proteotypes associated with patient survival differences. Proteotypes display distinctive active pathway features and associated candidate therapeutic targets. Signatures comprising proteotype markers effectively stratify orthogonal NSCLC primary tumors^12,14 as well as NSCLC DepMap cell lines²⁵, which enables a degree of candidate target validation and prioritization based on alignment with DepMap sensitivities²⁶.